RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor: Rapa Therapeutics LLC
Study ID: NCT04176380
Phase: PHASE2
Status: Completed

Conditions

Relapsed, Refractory Multiple Myeloma

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

RAPA-201 Autologous T cells — BIOLOGICAL
Autologous rapamycin resistant Th1/Tc1 cells

Study Details

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.

Key Dates

Start date: Dec 2, 2020
Status verified: May 2025
Primary completion: Jan 30, 2023
Completion: Jun 6, 2023

Study Design

Enrollment: 15 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Administration of RAPA-201 cells

Primary Outcome Measure

Overall response rate [ Time Frame: One (1) year after last dose of RAPA-201 cells. ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	-

Find similar trials in Milwaukee, WI

By research site

Medical College of Wisconsin· Milwaukee, WI